Yann Hamon 4:00 p.m., June 14, 2022
With its Future Trophies, Europe 1 rewards companies, associations or local authorities each year for their audacity, their innovation and their visionary side.
In the running for the Health Trophy, in partnership with Arthrtitis-Clarins, Carcidiag is developing cancer prognosis kits to ensure better care.
Carcidiag has developed a range of prognostic kits for cancer in patients already diagnosed.
These kits make it possible to define the aggressiveness of cancers in order to determine personalized care for each patient under treatment.
Research and development
All of the Carcidiag prognostic kits for oncologists and pathologists have been on the market since the beginning of 2022, after a period of more than three years for research and development.
Towards a better life expectancy
"Based on a biopsy performed on diagnosed patients, the kits will provide additional information that is essential for proper patient care. For example, patients with lung cancer at an early stage will be able to access complementary treatments with chemotherapy or radiotherapy; whereas until now they would only have had access to surgery", explains Vincent Carré, president of Carcidiag.
This treatment will improve the life expectancy of cancer patients.